Intec Pharma Ltd

The company's financials show resilient growth, with revenue advancing from $0.00 in Q2 2020 to $0.00 in Q1 2021. Gross profit remained healthy with margins at N/A in Q1 2021 compared to N/A in Q2 2020. Operating income hit -$4.18M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$3.65M. Net income dropped to -$4.23M, while earnings per share reached -$3.83. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.